Shanghai - Delayed Quote CNY

Jointown Pharmaceutical Group Co., Ltd (600998.SS)

Compare
5.26
+0.04
+(0.77%)
At close: December 27 at 3:00:03 PM GMT+8
Loading Chart for 600998.SS
DELL
  • Previous Close 5.22
  • Open 5.23
  • Bid 5.25 x --
  • Ask 5.26 x --
  • Day's Range 5.18 - 5.29
  • 52 Week Range 4.35 - 8.95
  • Volume 20,733,915
  • Avg. Volume 39,356,374
  • Market Cap (intraday) 26.523B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) 12.83
  • EPS (TTM) 0.41
  • Earnings Date --
  • Forward Dividend & Yield 0.25 (4.75%)
  • Ex-Dividend Date Jun 7, 2024
  • 1y Target Est --

Jointown Pharmaceutical Group Co., Ltd provides pharmaceutical supply chain services in China. It is also involved in general agency brand promotion; digital retail; intelligent logistics and supply chain solutions; and medical health and technology value-added service businesses. In addition, the company manufactures western medicines, such as antibiotics, anti-diabetic drugs, and cardiovascular drugs; and other OEM medicines. The company was founded in 1999 and is based in Wuhan, China.

www.jztey.com

30,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600998.SS

View More

Performance Overview: 600998.SS

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

600998.SS
21.52%
SSE Composite Index
14.29%

1-Year Return

600998.SS
22.62%
SSE Composite Index
17.29%

3-Year Return

600998.SS
11.78%
SSE Composite Index
6.02%

5-Year Return

600998.SS
7.69%
SSE Composite Index
13.06%

Compare To: 600998.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600998.SS

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    26.52B

  • Enterprise Value

    26.43B

  • Trailing P/E

    12.94

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.18

  • Price/Book (mrq)

    1.08

  • Enterprise Value/Revenue

    0.18

  • Enterprise Value/EBITDA

    6.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.37%

  • Return on Assets (ttm)

    2.67%

  • Return on Equity (ttm)

    7.15%

  • Revenue (ttm)

    149.2B

  • Net Income Avi to Common (ttm)

    2.05B

  • Diluted EPS (ttm)

    0.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.24B

  • Total Debt/Equity (mrq)

    43.63%

  • Levered Free Cash Flow (ttm)

    1.87B

Research Analysis: 600998.SS

View More

People Also Watch